News
-
-
PRESS RELEASE
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tharimmune, Inc. expands product pipeline with HS1940, a multispecific biologic targeting PD-1 and VEGF epitopes to enhance cancer treatment options. EpiClick™ Technology enables creation of novel therapeutics -
-
-
-
PRESS RELEASE
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Tharimmune, Inc. announces Phase 2 study for TH104 to treat pruritus in primary biliary cholangitis patients. Company achieved key milestones in 2024 -
-
-
-
PRESS RELEASE
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune, Inc. presents promising Phase 1 TH104 clinical data at The Liver Meeting® 2024, demonstrating significant correlation between blood levels and symptom relief in chronic liver disease patients
